Dr. Konstantinos Syrigos, MD, PhD, Oncologist

Konstantinos Syrigos, MD, PhD

Professor and Head, Oncology Unit GPP, Athens School of Medicine.

Visiting Professor of Thoracic Oncology, Yale School of Medicine, CT, USA.


Professor Kostas Syrigos graduated from Athens School of Medicine in 1988. He was trained in Internal Medicine at the Laikon University Hospital (Athens University) and in Medical Oncology at the Hammersmith Hospital (Imperial College of Medicine, Sciences & Art, London University). He got his MD thesis with distinction from the Athens School of Medicine, in 1995 and his PhD thesis from the Imperial College of Science, Technology and Medicine, London University, in 2000. He worked as Medical Oncologist Senior Registrar at the Hammersmith and St Bartholomew’s Hospitals, in London and as consultant at the Sotiria General Hospital, in Athens. In 2002 he was appointed Assc. Professor of Oncology in Medicine and Head of the Sotiria Oncology Unit. From 2006 he is also Visiting Professor of Thoracic Oncology at Yale University, CT, USA and from 2012 he is also Adjunct Professor of Medicine at Pittsburgh School of Medicine, USA. His main fields of interest are Targeted Therapies, drugs development as well as Thoracic and Head & Neck oncology.


Dr Syrigos participated in several international clinical trials Phase I-IV in lung, colon, head & neck and pancreatic cancer. He is a member of numerous scientific societies, including the European Society of Medical Oncology (ESMO), the European Respiratory Society (ERS), the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC).


He is a manuscript reviewer for 84 international scientific journals and currently serves on the editorial board of 18 international scientific journals. He is the editor of 9 International Scientific Volumes.  He has contributed 80 chapters in international books and he is the author of 360 peer-reviewed, international articles, with more than 5.000 citations. He is currently sitting as member of the ESMO Translational Research Group and of the MASCC Board of Directors.